SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (843)2/23/2001 12:48:10 AM
From: scaram(o)uche  Respond to of 1475
 
I've been bombarded with emails, private messages and phone calls re. my last post. Thanks, everyone.

I trained as a transplantation geneticist. I *know* why they bought Eligix. Furthermore, I was one of the first to cure lymphoid malignancies in an experimental model with GvH. I don't just think that this stuff is exciting, I *know* that it's exciting.

However, re. AlloMune........ I don't believe that anti-lymphoid malignancy and GvH can be separated as cleanly as it's being represented.

T cell removal for "standard" BMT...... it's been known for ages that a little "conditioning" is a good thing, that fewer stem cells are required for reconstitution if the preparation *is* contaminated by T cells. It's not as simple an issue as it seems.

B cell removal from marrow, prior to BMT for B cell malignancies? Is four logs of purification enough? I like the idea, but........... how often is BMT actually performed for B cell malignancies? It's a market that will need to be created.

Re. Eligix in general....... cellular therapies rarely (never??!!) achieve the predicted penetrations. Cost retrieval will, unfortunately, be the best we can expect for quite some time IMO.

The fit is excellent. However, I also feel that the deal dilutes potential payback for any 507 success.

I look forward to being proven wrong by Lebowitz et al. Would *love*to be wrong. The leverage is pronounced.

Go BTRN!!



To: scaram(o)uche who wrote (843)2/23/2001 11:39:47 PM
From: tuck  Read Replies (2) | Respond to of 1475
 
Rick,

>>First, I couldn't listen to the BIO CEO presentation, and, for some reason, it's not archived.<<

I had no trouble listening to the presentation. It is archived now, anyway, at a link you are familiar with:

informedinvestors.com

We await your post-listening opinion. It sounds to me like MEDI is finally getting on the stick. I'm tempted to buy here.

Cheers, Tuck